345P - Prognostic factors influencing the selection of bevacizumab combined with chemotherapy in patients with HER2-negative metastatic breast cancer in ro...

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Anticancer agents
Breast Cancer
Biological therapy
Presenter Luis Manso
Authors L. Manso1, R. Perez-Carrion2, J..I. Chacon Lopez-Muniz3, A. García Palomo4, E. Galve Calvo5, R.M. Llorente6, J. Casinello7, G. Catalán8, C. Llorca9, C. Grávalos10
  • 1Medical Oncology, Hopital 12 de Octubre, Madrid/ES
  • 2Oncology, Hospital Universitario Quiron, Madrid/ES
  • 3Oncolog, Hospital Virgen de la Salud, ES-49004 - Toledo/ES
  • 4Oncology, Hospital de León, Leon/ES
  • 5Oncology, Hospital de Basurto, Bilbao/ES
  • 6Oncology, Hospital Universitario Dr. Peset, Valencia/ES
  • 7Oncology, Hospital General Guadalajara, Guadalajara/ES
  • 8Oncology, Hospital Son Llatzer, Palma de Mallorca/ES
  • 9Oncology, Hospital de Elda, Alicante/ES
  • 10Medical Oncology, Hospital Doce de Octubre, Madrid/ES



Combining bevacizumab (BEV) with chemotherapy (CT) improves survival in HER2-negative metastatic breast cancer (MBC). We investigated the influence of age, ECOG, hormonal status, number of sites and location of metastases and patient decision on the selection of BEV combined with CT in MBC.


Observational cross-sectional multicenter study in pts with HER2- negative MBC who have received first-line CT with BEV.


From November 2010 to November 2011, 124 pts were included: median age 51 (45-64) yr; ECOG: 0 = 50%; 60% pre-menopausic; 23% triple-negative (TN); 77% hormone receptorpositive (HR+). Metastatic disease: ≥3 sites = 42% (TN: 32%; HR + : 45%); location: 44% bone, 35% lung, 30% liver. Most frequent BEV-based combinations were paclitaxel/BEV (53%) and docetaxel/BEV (14.5%); median no. of CT cycles: 6 (5-8). A disease-free survival (DFS) ≥12 months was achieved by 73%; TN: 68%; HR + : 76%. Overall response rate (ORR) was 58%: 51% partial response (PR), 7% complete response (CR); 28% stable disease (SD) and 10% disease progression. TN: ORR 44% (40% PR), clinical benefit 80% (36% SD); HR + : ORR 62% (54% PR), clinical benefit 87% (25% SD). 58% presented at least one toxicity, mainly grade 1-2; 26% BEV-related: only 3 (2.4%) grade 3 toxicities; no grade 4. Receiving adjuvant hormonal therapy was associated to DFS ≥12 months (p < 0.05). ER+ tumors (OR: 0.215; 95% CI: 0.08-0.56; p = 0.002) and one metastatic site, vs. ≥3 sites (OR: 0.309; 95% CI: 0.12-0.83; p = 0.020) were independent factors associated with the selection of paclitaxel-BEV therapy in the overall population (TN or HR+). Metastases in the liver were significantly related to paclitaxel-BEV administration (p < 0.01).


Our findings suggest that first-line CT with BEV is an active and tolerable treatment option for pts with TN and HR+ MBC. ER+ tumors and a single metastatic site were identified as independent factors for the selection of a paclitaxel-BEV therapy. The presence of metastases in the liver was significantly associated to the administration of a paclitaxel-BEV regimen.


All authors have declared no conflicts of interest.